Identify MoA of the UCHT1 domain within the TAC receptor

Triumvira a, Canadian US, post series A, biotech company, working on the development of a new targeted cancer therapies. The core technology is focused on the genetic engineering of immune cells isolated from patients. This process then enables these immune cells to recognise cancer cells that otherwise are invisible to the immune system. These therapies are ideally suited for a systemic eradication of malignant tumor cells. Future refinement of this core technology requires a detailed biological understanding of the core mechanisms that drives the ability of engineered immune cells to specifically recognize and kill cancer cells. The candidate’s project focuses on research that will help Triumvira to better understand their core technology. This knowledge will is expected to enable Triumvira to further refine its core technology providing even more potent anti tumor therapies.

Faculty Supervisor:

Walid Houry

Student:

Partner:

Triumvira Immunologics

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

University of Toronto

Program: